Bank of America Securities analyst Tazeen Ahmad has initiated coverage on Immix Biopharma with a Buy rating and a price target of $27, driven by the potential of NXC-201 in treating AL amyloidosis. The firm estimates a 50% likelihood-of-success and models worldwide risk-adjusted peak sales of $963 million, assuming a U.S. launch in 2028 based on current timelines. This bullish outlook is supported by recent clinical data showing a 95% complete response rate, though the firm flags risks regarding safety and commercial adoption.

Strong Clinical Data Supports Bullish View

In an investor note, Bank of America Securities highlighted NXC-201 as a compelling opportunity in relapsed/refractory AL amyloidosis due to high complete response (CR) rates and the lack of approved therapies. In May, Immix Biopharma reported that 19 of the first 20 patients treated with NXC-201 achieved a complete response within one year, with no relapses reported to date. The company plans to begin a Phase 3 trial in newly diagnosed patients, with the next clinical update expected in September 2026. In January, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to NXC-201 for relapsed/refractory AL Amyloidosis based on Phase 2 interim data from the NEXICART-2 trial.

BofA Highlights Risks To Commercial Adoption

Despite the positive rating, BofA questions whether the early high CR rates will hold up with longer follow-up. Safety remains a critical concern for this frail population, as even modest increases in cytokine release syndrome, neurotoxicity, or cardiac events could limit real-world adoption. Access may also constrain near-term uptake, with CAR-T manufacturing, logistics, and treatment center capacity potentially limiting use as demand for other CAR-T therapies grows. Risks to the Buy thesis include durability uncertainty, potential safety issues in larger studies, emerging competition, and a slower-than-expected commercial ramp.